H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on BioCardia (BCDA – Research Report) today and set a price target of $4.00. The company’s shares opened today at $0.55.
According to TipRanks, Pantginis is an analyst with an average return of -8.4% and a 30.20% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as BioCardia, Panbela Therapeutics, and Krystal Biotech.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioCardia with a $4.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
BCDA market cap is currently $12.54M and has a P/E ratio of -0.86.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioCardia, Inc. operates as a clinical-stage regenerative medicine company. It develops novel therapeutics for cardiovascular diseases. The firm offers proprietary comprehensive biotherapeutic solutions for cardiovascular disease under the CardiAMP and CardiALLO brand. It operates in only one business segment, which is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The company was founded on January 12, 1994 and is headquartered in San Carlos, CA.
Read More on BCDA:
- BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs
- BioCardia reports interim efficacy results in Phase 3 CardiAMP Cell Therapy
- BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial
- BioCardia reports Q2 EPS (17c), consensus (16c)
- BioCardia Reports Second Quarter 2023 Business Highlights and Financial Results
